After a period of protracted uncertainty, a new report asserts the long-awaited market for biosimilars appears to be taking off in the U.S. and is on track to reduce overall spending on medicines by $100 billion over the next five years.
So far, the 22 biosimilars available in the U.S. have a combined 20% market share, which represents about 16% of all biologic sales, according to the IQVIA Institute for Human Data Science, which issued the report. Notably, the first biosimilar version of Avastin —a widely prescribed cancer medicine — reached 42% of the market in June, just one year after being launched.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
Biosimiliars have come a long way and that’s great news for patients. I can remember when some industry players resisted their introduction. There were even rumors of some industry reps saying biosimiliars would never work.